Survodutide
The Liver-Targeting Weight Loss Drug
Survodutide combines GLP-1 with glucagon receptor activation for powerful weight loss AND breakthrough fatty liver disease treatment. It could be the first drug to treat both conditions simultaneously.
What Is Survodutide?
Survodutide (BI 456906) is a dual receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates both GLP-1 receptors (like Ozempic) and glucagon receptors—a unique combination that targets both appetite and metabolism.
Why glucagon? While glucagon is often associated with raising blood sugar, when combined with GLP-1, it dramatically increases energy expenditure and promotes fat burning—especially in the liver. This makes Survodutide particularly promising for fatty liver disease.
Administration: Once-weekly subcutaneous injection, similar to other GLP-1 medications.
The Dual Mechanism
GLP-1 Agonism
- • Reduces appetite and food intake
- • Slows gastric emptying
- • Improves insulin secretion
- • Lowers blood sugar
- • Proven weight loss mechanism
Glucagon Agonism
- • Increases energy expenditure
- • Promotes fat oxidation
- • Dramatically reduces liver fat
- • Improves lipid profiles
- • Enhances weight loss beyond GLP-1 alone
Survodutide vs Mounjaro
While both are dual agonists, they target different second receptors. Mounjaro = GLP-1 + GIP (enhances insulin). Survodutide = GLP-1 + Glucagon (burns fat, especially liver fat). This makes Survodutide uniquely positioned for fatty liver disease.
Breakthrough MASH Results
MASH (metabolic dysfunction-associated steatohepatitis), formerly called NASH, affects over 15 million Americans. There are currently NO approved treatments—until now.
In Phase 2 trials, 83% of patients on the highest dose achieved MASH resolution without worsening fibrosis. This is the highest rate ever seen in a MASH trial—a potential game-changer for liver disease treatment.
52% of patients showed fibrosis improvement by at least one stage. Fibrosis (liver scarring) was previously considered largely irreversible—this suggests Survodutide may actually reverse liver damage.
Patients experienced up to 87% relative reduction in liver fat content. The glucagon component specifically drives fat out of the liver, addressing the root cause of MASH.
Weight Loss Results
Phase 2 trials evaluated Survodutide for obesity over 46 weeks in adults with BMI ≥27 kg/m².
At the highest dose (4.8mg weekly), participants lost an average of 18.7% of their body weight over 46 weeks—comparable to tirzepatide (Mounjaro).
A significant percentage of participants achieved greater than 20% weight loss. Top responders lost over 25% of their body weight.
Expected Dosing Schedule
Based on clinical trials, Survodutide follows a gradual dose escalation:
Note: Final dosing will be established by Phase 3 trials. Some patients may achieve optimal results at lower doses.
Side Effects
Common (GI-Related)
- • Nausea (most common)
- • Vomiting
- • Diarrhea
- • Decreased appetite
- • Constipation
Glucagon-Related Considerations
- • Increased heart rate (mild)
- • Potential blood sugar effects (balanced by GLP-1)
- • Effects typically manageable
- • Dose escalation reduces severity
Safety note: The GLP-1 component effectively prevents glucagon from raising blood sugar. In trials, Survodutide improved glycemic control despite the glucagon component.
Development Timeline
Who Will Benefit Most?
Ideal Candidates
- • Patients with fatty liver disease (MASH/NAFLD)
- • Obesity with elevated liver enzymes
- • Those who haven't responded well to other GLP-1s
- • Patients wanting metabolic + liver benefits
- • Type 2 diabetics with liver concerns
The MASH Opportunity
MASH affects millions and can progress to cirrhosis and liver cancer. With no approved treatments, Survodutide could be the first FDA-approved medication for this condition.
If you have elevated ALT/AST, fatty liver on imaging, or diagnosed NAFLD/MASH, Survodutide may be particularly relevant for you.
Survodutide vs Other Dual Agonists
| Drug | Mechanism | Weight Loss | Liver Benefits |
|---|---|---|---|
| Survodutide | GLP-1 + Glucagon | ~19% | Excellent (83% MASH resolution) |
| Mounjaro/Zepbound | GLP-1 + GIP | ~18-21% | Moderate |
| Cagrisema | GLP-1 + Amylin | ~22-25% | Moderate |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | Very Good (86% liver fat reduction) |
Frequently Asked Questions
Will Survodutide raise my blood sugar?
No. While glucagon alone raises blood sugar, the GLP-1 component in Survodutide effectively counteracts this. Clinical trials showed improved glycemic control, not worsened. The combination is designed to be safe for diabetics.
Is Survodutide only for people with liver disease?
No. Survodutide is being developed for both obesity AND MASH. You don't need liver disease to potentially benefit from its weight loss effects. However, if you do have fatty liver, Survodutide may offer additional benefits other GLP-1s don't provide.
How does Survodutide compare to Retatrutide for liver disease?
Both show excellent liver benefits due to their glucagon components. Survodutide's Phase 2 MASH data (83% resolution) is slightly ahead of Retatrutide's liver data, though direct comparisons are difficult without head-to-head trials.
When will Survodutide be available?
Phase 3 trials are ongoing. If successful, FDA submission could occur in 2026, with potential approval in 2027. MASH indication may be approved before or alongside obesity indication.
Track Your Metabolic Health Journey
Whether you're managing weight, blood sugar, or liver health, Shotlee helps you track progress across all your health metrics.
Start Tracking Free